Changing the 340B patient definition “might reduce hospitals’ and physicians’ incentives to consolidate,” but to what extent “remains highly uncertain,” the Congressional Budget Office says in a new policy analysis.
House Budget Committee Chair John Yarmuth (D-Ky.) asked CBO to
…
Drug manufacturer UCB has sued in federal court to overturn federal health officials’ finding that the Belgian company’s restrictions on 340B pricing when covered entities use contract pharmacies are illegal and must stop or the company could face civil monetary
…
As we first reported Friday in a news alert, a federal appeals court in Philadelphia has tentatively scheduled oral arguments in three key 340B contract pharmacy lawsuits for Nov. 15.
The clerk of the U.S. Third Circuit Court of Appeals
…
The U.S. Health Resources and Services Administration (HRSA) has granted Florida and South Carolina 340B program enrollment flexibility, as public health emergencies (PHEs) were declared in both states in the aftermath of Hurricane Ian, which left widespread destruction, flooding, and
…
The U.S. Department of Health and Human Services Office of Inspector General (HHS OIG) has informed a bipartisan group of House lawmakers that the enforcement agency does not plan to impose civil monetary penalties against the drug makers that have
…
In a big victory for 340B hospitals, a federal judge in Washington, D.C. ruled yesterday that the government must immediately begin to pay 340B hospitals the full Medicare Part B drug payment rate for the remainder of calendar year (CY)
…
Shockwaves from the New York Times’ investigative piece on the alleged misuse of 340B savings by a Catholic health system in Richmond, Virginia continues to spread, as local news outlets and government leaders from all levels respond. The lengthy article
…
Government health officials need to take immediate action to fully enforce the law against drug makers who are denying 340B drug discounts to providers who use contract pharmacies to dispense 340B-priced drugs, U.S. Senator Joe Manchin (D-W.VA.) and U.S. Senator
…
The U.S. Health Resources Services Administration (HRSA) has ordered South Carolina-based VistaPharm, a manufacturer of generic and over-the-counter (OTC) drugs to repay overcharges to 340B covered entities after a HRSA audit showed the company did not offer its products at the
…
Sparked by the dismissal of its complaint against Astra Zeneca and Sanofi by the government’s Administrative Dispute Resolution Panel (ADR), the National Association of Community Health Centers say “they cannot wait any longer for a solution,” to the two-year standoff
…*Sign up for news summaries and alerts from 340B Report